SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:lup.lub.lu.se:19aabc30-bc7c-4935-8082-7d7020ef7825"
 

Search: id:"swepub:oai:lup.lub.lu.se:19aabc30-bc7c-4935-8082-7d7020ef7825" > A retrospective stu...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003496naa a2200373 4500
001oai:lup.lub.lu.se:19aabc30-bc7c-4935-8082-7d7020ef7825
003SwePub
008160404s2010 | |||||||||||000 ||eng|
024a https://lup.lub.lu.se/record/16447552 URI
024a https://doi.org/10.1097/MBC.0b013e32833c9ab92 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
100a Berntorp, Eriku Lund University,Lunds universitet,Klinisk koagulationsmedicin, Malmö,Forskargrupper vid Lunds universitet,Clinical Coagulation, Malmö,Lund University Research Groups4 aut0 (Swepub:lu)medf-ebe
2451 0a A retrospective study of Octaplex in the treatment of bleeding in patients with haemophilia A complicated by inhibitors.
264 1c 2010
520 a The nonactivated prothrombin complex concentrate (PCC) Octaplex (Octapharma PPGmbH, Vienna, Austria) has been used successfully for the treatment of congenital and acquired coagulation factor deficiencies and associated bleeding. The aims of this study were to assess retrospectively whether Octaplex is an effective treatment option for haemophilia A patients with high-titre inhibitors of factor VIII (FVIII) and to investigate the impact of Octaplex on thrombin generation in vitro and ex vivo. Retrospective data were collected from 15 haemophilia A patients with FVIII inhibitors who had been treated with Octaplex. Mild bleeds were treated for a median of 1 day with a median dose of 77 IU/kg and moderate bleeds for 3 days with 57 IU/kg. The physician's overall satisfaction with Octaplex, taking into account efficacy, safety and cost in comparison with other treatment options, was assessed for each bleed. The overall rating was good, very good or excellent for 29 of 41 (71%) bleeds. No adverse drug reactions were reported. In in-vitro studies of thrombin generation with normal plasma samples, experimental inhibition of FVIII activity prolonged the lag phase, diminished the peak thrombin concentration and decreased the area under the concentration-time curve, as expected. Marked improvement in thrombin generation parameters was achieved by adding 0.5-3 IU factor IX/ml PCC into the samples. The same held true when using plasma samples from haemophilia A patients with FVIII inhibitors. These results demonstrate that Octaplex overcomes inhibition of FVIII in in-vitro and ex-vivo assays of thrombin generation, and that Octaplex is an effective treatment option for haemophilia A patients with FVIII inhibitors.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
700a Figueiredo, Sandra4 aut
700a Futema, Lucimara4 aut
700a Pock, Katharina4 aut
700a Knaub, Sigurd4 aut
700a Walter, Olaf4 aut
700a Trawnicek, Laurenz4 aut
700a Römisch, Jürgen4 aut
710a Klinisk koagulationsmedicin, Malmöb Forskargrupper vid Lunds universitet4 org
773t Blood Coagulation and Fibrinolysisg 21, s. 577-583q 21<577-583x 1473-5733
856u http://www.ncbi.nlm.nih.gov/pubmed/20644466?dopt=Abstracty FULLTEXT
856u http://dx.doi.org/10.1097/MBC.0b013e32833c9ab9y FULLTEXT
8564 8u https://lup.lub.lu.se/record/1644755
8564 8u https://doi.org/10.1097/MBC.0b013e32833c9ab9

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view